Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Saturday.

According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “

A number of other brokerages also recently weighed in on TTPH. BMO Capital Markets raised their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. Finally, HC Wainwright began coverage on Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a “buy” rating and a $15.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $14.75.

Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $6.36 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The business had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. During the same period last year, the business earned ($0.58) EPS. The firm’s revenue was up 355.6% compared to the same quarter last year. equities analysts forecast that Tetraphase Pharmaceuticals will post -2.86 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades Tetraphase Pharmaceuticals, Inc. (TTPH) to Sell” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/zacks-investment-research-downgrades-tetraphase-pharmaceuticals-inc-ttph-to-sell/1681617.html.

In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,155 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $5.86, for a total value of $41,928.30. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders sold 33,405 shares of company stock worth $199,691. Company insiders own 5.50% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC increased its position in shares of Tetraphase Pharmaceuticals by 18.6% during the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 2,496 shares during the period. UBS Group AG increased its position in shares of Tetraphase Pharmaceuticals by 2.3% during the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 387 shares during the period. AXA bought a new stake in shares of Tetraphase Pharmaceuticals during the second quarter valued at approximately $132,000. Jane Street Group LLC bought a new stake in shares of Tetraphase Pharmaceuticals during the first quarter valued at approximately $181,000. Finally, Voya Investment Management LLC increased its position in shares of Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 3,104 shares during the period. Institutional investors and hedge funds own 40.92% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.